Guo, C., Huang, T., Chen, A., Chen, X., Wang, L., Shen, F., & Gu, X
This creates a positive cycle where initial weight loss makes blood sugar easier to control, which in turn supports continued weight management
Similarly, SGLT2 inhibitors have demonstrated robust cardiovascular and renal benefits, including reductions in cardiovascular events and all-cause mortality, with consistent effects across the drug class and irrespective of diabetes status [6, 7] Their metabolic benefitssuch as weight loss, improved lipid profiles, and reduced visceral adipositycontribute to a favourable cardiovascular risk profile, countering the pro-atherogenic state typical of T2DM [8]
PlexusDx coordinates these monitoring touchpoints with your rheumatologist
doi: 10.1038/nm.3128 206 SmitsMMTen KulveJSvan BloemendaalLTonneijckLMuskietMHAKramerMHHet al